Objectives: This study aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under the operational research conditions compared to DR-TB patients treate...Objectives: This study aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under the operational research conditions compared to DR-TB patients treated without bedaquiline in their regimen, and to describe the adverse events that occurred among patients treated with bedaquiline in the Philippines. Design: Patients who were treated with a bedaquiline-containing regimen from June 2016 to May 2017 were included in this study as the intervention group, while patients who were treated without bedaquiline regimen from January 2013 to May 2016 were included as the comparison group. The interim treatment outcomes were compared using Chi-square test. The analysis of time to culture conversion within 6 months of treatment was conducted. A Cox proportional hazard model was constructed to identify the variables associated with a favorable interim treatment outcome. The R program was used for statistical analysis. Results: On the 6th month of treatment, the culture conversion for patients treated with a bedaquiline-containing regimen was significantly higher than with the comparison group [63/75 (84.0%) vs 84/117 (71.8%), p = 0.012)]. Nearly 15% of the patients treated with bedaquiline were lost to follow-up. Frequent adverse events included vomiting, dizziness, nausea, joint pain, and abdominal pain. Conclusion: The patients who were treated with bedaquiline-containing regimen have better interim treatment outcomes than those treated without bedaquiline, but the proportion of patients who were lost to follow-up remains substantial.展开更多
Sustained heavy ethanol drinking is a common problem globally and ethanol is one of the most abused drugs among individuals of different socio-economic status including the HIV-infected patients on antiretroviral drug...Sustained heavy ethanol drinking is a common problem globally and ethanol is one of the most abused drugs among individuals of different socio-economic status including the HIV-infected patients on antiretroviral drugs. Ethanol is reward drug and a CNS depressant especially at high doses. The study determined the effect of sustained heavy ethanol drinking by HIV-infected patients on d4T/3TC/NVP regimen on CD4+ cell counts in Uganda using WHO AUDIT tool and chronic alcohol-use biomarkers. A case control study using repeated measures design with serial measurements model was used. The patients on stavudine (d4T) 30 mg, lamivudine (3TC) 150 mg and nevirapine (NVP) 200 mg and chronic alcohol use were recruited. A total of 41 patients (20 in alcohol group and 21 in control group) were screened for chronic alcohol use by WHO AUDIT tool and chronic alcohol use biomarkers. They were followed up for 9 months with blood sampling done at 3 months intervals. CD4+ cell count was determined using Facscalibur Flow Cytometer system. Results were then sorted by alcohol-use biomarkers (GGT, MCV and AST/ ALT ratio). Data were analysed using SAS 2003 version 9.1 statistical package with repeated measures fixed model and the means were compared using student t-test. The mean CD4+ cell counts in all the groups were lower than the reference ranges at baseline and gradually increased at 3, 6 and 9 months of follow-up. The mean CD4+ cell counts were higher in the control group as compared to the chronic alcohol use group in both WHO AUDIT tool group and chronic alcohol-use biomarkers group though there was no significant difference (p > 0.05). Chronic alcohol use slightly lowers CD4+ cell count in HIV-infected patients on d4T/3TC/NVP treatment regimen.展开更多
目的:探讨肾脏替代治疗患者中万古霉素使用研究领域的现况和趋势。方法:基于Web of Science Core Collection,对2007年1月1日至2023年10月11日发表的肾脏替代治疗患者中万古霉素使用研究的相关文献进行检索。采用VOSviewer和CiteSpace...目的:探讨肾脏替代治疗患者中万古霉素使用研究领域的现况和趋势。方法:基于Web of Science Core Collection,对2007年1月1日至2023年10月11日发表的肾脏替代治疗患者中万古霉素使用研究的相关文献进行检索。采用VOSviewer和CiteSpace软件进行文献计量学和可视化分析,涉及发表趋势、地理分布特征、作者及机构、期刊分布特征和关键词信息等。结果:共纳入747篇文献。2007年以来,相关领域发文量波动上升,美国(264篇)是发文量最多的国家,其次为澳大利亚(76篇)和中国(71篇)。昆士兰大学(49篇)出版物最多。Jason A Roberts(24篇)、David W Johnson (19篇)和Jeffrey Lipman(19篇)是发文量居前3位的作者。《Peritoneal Dialysis International》(47篇)是发表相关文献最多的期刊。近年来的关键词聚焦于急性肾损伤、给药方案、治疗药物监测、群体药动学以及连续肾脏替代治疗等主题。结论:肾脏替代治疗患者中万古霉素的最佳使用剂量尚不清楚。通过治疗药物监测及群体药动学建模等方法,给予患者合适的给药方案,从而达到抗感染疗效并规避不良反应是该领域的热点和趋势。我国的研究机构与国际间缺乏紧密的合作交流。展开更多
文摘Objectives: This study aimed to assess the interim outcomes for drug-resistant tuberculosis (DR-TB) patients treated with bedaquiline regimen under the operational research conditions compared to DR-TB patients treated without bedaquiline in their regimen, and to describe the adverse events that occurred among patients treated with bedaquiline in the Philippines. Design: Patients who were treated with a bedaquiline-containing regimen from June 2016 to May 2017 were included in this study as the intervention group, while patients who were treated without bedaquiline regimen from January 2013 to May 2016 were included as the comparison group. The interim treatment outcomes were compared using Chi-square test. The analysis of time to culture conversion within 6 months of treatment was conducted. A Cox proportional hazard model was constructed to identify the variables associated with a favorable interim treatment outcome. The R program was used for statistical analysis. Results: On the 6th month of treatment, the culture conversion for patients treated with a bedaquiline-containing regimen was significantly higher than with the comparison group [63/75 (84.0%) vs 84/117 (71.8%), p = 0.012)]. Nearly 15% of the patients treated with bedaquiline were lost to follow-up. Frequent adverse events included vomiting, dizziness, nausea, joint pain, and abdominal pain. Conclusion: The patients who were treated with bedaquiline-containing regimen have better interim treatment outcomes than those treated without bedaquiline, but the proportion of patients who were lost to follow-up remains substantial.
文摘Sustained heavy ethanol drinking is a common problem globally and ethanol is one of the most abused drugs among individuals of different socio-economic status including the HIV-infected patients on antiretroviral drugs. Ethanol is reward drug and a CNS depressant especially at high doses. The study determined the effect of sustained heavy ethanol drinking by HIV-infected patients on d4T/3TC/NVP regimen on CD4+ cell counts in Uganda using WHO AUDIT tool and chronic alcohol-use biomarkers. A case control study using repeated measures design with serial measurements model was used. The patients on stavudine (d4T) 30 mg, lamivudine (3TC) 150 mg and nevirapine (NVP) 200 mg and chronic alcohol use were recruited. A total of 41 patients (20 in alcohol group and 21 in control group) were screened for chronic alcohol use by WHO AUDIT tool and chronic alcohol use biomarkers. They were followed up for 9 months with blood sampling done at 3 months intervals. CD4+ cell count was determined using Facscalibur Flow Cytometer system. Results were then sorted by alcohol-use biomarkers (GGT, MCV and AST/ ALT ratio). Data were analysed using SAS 2003 version 9.1 statistical package with repeated measures fixed model and the means were compared using student t-test. The mean CD4+ cell counts in all the groups were lower than the reference ranges at baseline and gradually increased at 3, 6 and 9 months of follow-up. The mean CD4+ cell counts were higher in the control group as compared to the chronic alcohol use group in both WHO AUDIT tool group and chronic alcohol-use biomarkers group though there was no significant difference (p > 0.05). Chronic alcohol use slightly lowers CD4+ cell count in HIV-infected patients on d4T/3TC/NVP treatment regimen.
文摘目的:探讨肾脏替代治疗患者中万古霉素使用研究领域的现况和趋势。方法:基于Web of Science Core Collection,对2007年1月1日至2023年10月11日发表的肾脏替代治疗患者中万古霉素使用研究的相关文献进行检索。采用VOSviewer和CiteSpace软件进行文献计量学和可视化分析,涉及发表趋势、地理分布特征、作者及机构、期刊分布特征和关键词信息等。结果:共纳入747篇文献。2007年以来,相关领域发文量波动上升,美国(264篇)是发文量最多的国家,其次为澳大利亚(76篇)和中国(71篇)。昆士兰大学(49篇)出版物最多。Jason A Roberts(24篇)、David W Johnson (19篇)和Jeffrey Lipman(19篇)是发文量居前3位的作者。《Peritoneal Dialysis International》(47篇)是发表相关文献最多的期刊。近年来的关键词聚焦于急性肾损伤、给药方案、治疗药物监测、群体药动学以及连续肾脏替代治疗等主题。结论:肾脏替代治疗患者中万古霉素的最佳使用剂量尚不清楚。通过治疗药物监测及群体药动学建模等方法,给予患者合适的给药方案,从而达到抗感染疗效并规避不良反应是该领域的热点和趋势。我国的研究机构与国际间缺乏紧密的合作交流。
